Vizient Epi+Gen CHD™

0020714

EGCHD

Ordering Recommendation

Assess three-year risk for a coronary heart disease event (heart attack, sudden death associated with coronary heart disease). Rx only.

Methodology

An integrated epigenetic-genetic test for assessing the three-year coronary heart disease event risk assessment was developed using data from subjects from the Framingham Heart Study and validated using data from subjects from the Intermountain Healthcare INSPIRE registry.

Performed

Monday-Friday

Reported

Within 7-10 business days of receiving the blood sample

Geographic Restrictions

This test is not eligible to be performed in patients from New York

Specimen Required

Patient Preparation:

Collect: 2 mL blood sample (vacutainer) or 500uL (microtainer)

Specimen Preparation: 2mL BD K2EDTA vacutainer or 500uL BD K2EDTA microtainer and lancet

Storage/Transport Temperature: Room temperature

Unacceptable Conditions: Specimen must be shipped the same day of collection. Delayed shipment of the specimen may result in the specimen being rejected.

Remarks: Specimen collection information and a test requisition form must be provided

Interpretive Data

Epi+Gen CHD™ risk report captures certain complex genetic and environmental (epigenetic) relationships that contribute to the risk of a coronary heart disease event. A risk category (low, borderline, intermediate, or high) is provided. Epi+Gen CHD™ is a Laboratory Developed Test (LDT).